(Q51411890)

5 April 2018

title

Nebulized and intranasal fentanyl in the management of cancer-related breakthrough pain. (English)

1 reference

5 April 2018

0 references

1 reference

G Zeppetella

1

1 reference

5 April 2018

publication date

1 January 2000

1 reference

5 April 2018

published in

Palliative Medicine

1 reference

5 April 2018

volume

14

1 reference

5 April 2018

issue

1

1 reference

5 April 2018

page(s)

57-58

1 reference

5 April 2018

A review of oral transmucosal fentanyl citrate: potent, rapid and noninvasive opioid analgesia

cites work

1 reference

https://api.crossref.org/works/10.1191%2F026921600668793500

Inhaled fentanyl as a method of analgesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F026921600668793500

Breakthrough pain: definition, prevalence and characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F026921600668793500

Treatment outcome in a multidisciplinary cancer pain clinic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F026921600668793500

Characterization of breakthrough pain by hospice patients and their caregivers

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F026921600668793500

Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F026921600668793500

10.1191/026921600668793500

21 January 2018

Identifiers

DOI

1 reference

5 April 2018

1 reference

5 April 2018